Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Videos|February 23, 2021
Living Through an Episode
Author(s)Susan J. Noonan, MD, MPH
When dealing with a serious mental illness, speaking out and sharing common experiences can help healing.
Advertisement
Susan J. Noonan, MD, MPH, talks about how finding a community and sharing experiences can help people going through an episode.
Dr Noonan is a physician consultant and Certified Peer Specialist in the Department of Psychiatry at McLean Hospital and the Massachusetts General Hospital. She is the author of four books and a blog on managing depression, most recently
Advertisement
Related to this article
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5